TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02041533
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03454763
Drug: PRRT every 5 weeks
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PRRT (radiolabelled somatostatin analogues) every 5 weeks for 5 cycles
Study: NCT03454763
Drug: PRRT every 8-10 weeks
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PRRT (radiolabelled somatostatin analogues) every 8-10 weeks for 5 cycles
Study: NCT02117024
Drug: Viagenpumatucel-L
Normalized name: Viagenpumatucel-L
DrugBank: Viagenpumatucel-L (DB16348)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
Study: NCT00981656
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60-minute intravenous (IV) infusion of 15 mg/m\^2 on days 1, 2, 3, 15, 16, 17, 29, 30, and 31 of radiation treatment.
Study: NCT00981656
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous IV infusion of 500 mg/m\^2/24 hrs for 5 consecutive days during weeks 1 and 4 of radiation treatment.
Study: NCT00981656
Drug: Mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV bolus dose of 12 mg/m\^2 on day 1 of radiation treatment.
Study: NCT00287105
Drug: Standard chemotherapy + Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients receive Imatinib together with the standard chemotherapy regimen of phase IB and after each of three consecutive blocks of the standard chemotherapy in the consolidation phase
Study: NCT04414241
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A loading dose of 600mg of hydroxychloroquine orally on the first day, followed by 400mg of hydroxychloroquine orally every-other-day and use of standard measures of personal protection provided from the hospital for 8 weeks.
Study: NCT00989911
Drug: Bosentan
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan 62.5 mg tablet taken orally twice daily for one month, followed by Bosentan 125 mg tablet taken orally twice daily for three months.
Study: NCT00837434
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50 mg dose of etanercept by subcutaneous injection
Study: NCT00837434
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 40 mg dose of adalimumab by subcutaneous injection
Study: NCT02275702
Drug: Dexamethasone IV
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: It will be administered at the induction of the anesthesia
Study: NCT02275702
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02367690
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical gel
Study: NCT01077310
Drug: Vivitrol- Intramuscular naltrexone (depot-formulation)
Normalized name: naltrexone Injection [Vivitrol]
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
Study: NCT00070837
Drug: MLN2704 (DM1 conjugated monoclonal antibody MLN591)
Normalized name: Conjugated Estrogens
DrugBank: MLN2704 (DB06513)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00198510
Drug: Vitrase
Normalized name: Vitrase
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 IU of Vitrase
Study: NCT00198510
Drug: Vitrase
Normalized name: Vitrase
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 55 IU of Vitrase
Study: NCT00198510
Drug: Vitrase
Normalized name: Vitrase
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 IU of Vitrase
Study: NCT00527046
Drug: CP-424,391
Normalized name: CP-424,391
DrugBank: Capromorelin (DB15205)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01878786
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus .
Study: NCT01878786
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus.
Study: NCT01878786
Drug: Mycophenolate mofetil (MMF/MPA)
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Control Drug
Study: NCT01712763
Drug: degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 180 women will be treated with degarlix 120 mg, in only one administration covering three months
Study: NCT01712763
Drug: Leuprolide Acetate 11.25 MG/ML (Enantone 11,25)
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 women will be treated with leuprolide acetate11.25 only once covering three months
Study: NCT00772538
Drug: tiotropium 5mcg/day
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention = randomisation: Patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo
Study: NCT00436332
Drug: erlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01779830
Drug: Zolpidem - Tablets
Normalized name: zolpidem Oral Tablet
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally as tablets.
Study: NCT01824238
Drug: Anacetrapib
Normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01824238
Drug: Placebo for anacetrapib
DrugBank: Anacetrapib (DB06630)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00166803
Drug: Rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone , 4 mg daily
Study: NCT00808132
Drug: bazedoxifene 20 mg/ conjugated estrogens 0.45 mg
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One capsule, bazedoxifene 20 mg/conjugated estrogens 0.45 mg (over-encapsulated), once a day for one year.
Study: NCT00808132
Drug: bazedoxifene 20 mg/ conjugated estrogens 0.625 mg
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One capsule, bazedoxifene 20 mg/conjugated estrogens 0.625 mg (over-encapsulated), once a day for one year.
Study: NCT00808132
Drug: bazedoxifene 20 mg
Normalized name: bazedoxifene 20 MG
DrugBank: Bazedoxifene (DB06401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One capsule, bazedoxifene 20 mg (over-encapsulated), once a day for one year.
Study: NCT00808132
Drug: conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One capsule, conjugated estrogens 0.45 mg and medroxyprogesterone 1.5 mg (over-encapsulated), once a day for one year.
Study: NCT02497599
Drug: Indium-111-DOTA-Girentuximab-IRDye800CW
DrugBank: Girentuximab (DB05304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indium-111-DOTA-Girentuximab-IRDye800CW tracer injection will be administered 7 days before (partial) nephrectomy
Study: NCT00270816
Drug: Interferon-ß-1b
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 micrograms (8 MIU) administered subcutaneously (sc) every other day with a discontinuance month every 2 months
Study: NCT00270816
Drug: Interferon ß-1b
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 micrograms (8 MIU) administered subcutaneously (sc) every other day
Study: NCT02405091
Drug: NBI-98854
Normalized name: NBI-98782
DrugBank: NBI-98782 (DB16905)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02470286
Drug: SA001 60mg or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Study Drug: SA001 60mg~* Comparator: Placebo~* Cohort 1 in the part 1 (Dose escalation study)
Study: NCT01695941
Drug: Alisertib
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01695941
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given SC
Study: NCT00531466
Drug: tolperisone HCl (AV650)
Normalized name: tolperisone
DrugBank: Tolperisone (DB06264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet orally three times a day for 28 days
Study: NCT00309361
Drug: Phentolamine Mesylate (NV-101)
Normalized name: Phentolamine Mesylate
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00404196
Drug: Calcipotriol and LEO80122 (LEO19123 cream)
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02470286
Drug: SA001 120mg or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Study Drug: SA001 120mg~* Comparator: Placebo~* Cohort 2 in the part 1 (Dose escalation study) and part 2 (Food effect study)
Study: NCT02470286
Drug: SA001 180mg or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Study Drug: SA001 180mg~* Comparator: Placebo~* Cohort 3 in the part 1 (Dose escalation study)
Study: NCT00090324
Drug: quetiapine fumarate tablets
Normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02470286
Drug: SA001 240mg or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Study Drug: SA001 240mg~* Comparator: Placebo~* Cohort 4 in the part 1 (Dose escalation study)
Study: NCT02470286
Drug: SA001 300mg or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Study Drug: SA001 300mg~* Comparator: Placebo~* Cohort 5 in the part 1(Dose escalation study) and part 2 (Food effect study)
Study: NCT03547908
Drug: DTG
Normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg tablet administered orally once daily, without regard to food
Study: NCT03547908
Drug: F/TDF
Normalized name: Emtricitabine/Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200/300 mg tablet administered orally once daily, without regard to food
Study: NCT02944110
Drug: Glucagon receptor antagonist LY2409021
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: single oral dose of 300mg
Study: NCT01001221
Drug: cabazitaxel
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: 60 mg/1.5 ml concentrate solution for infusion~Route of administration: Intravenous infusion over 60 minutes~Dosage:~* Study part 1: 15, 20 or 25 mg/m\^2 according to pre-defined dose escalation schedule~* Study part 2: MTD as determined in Study part 1
Study: NCT01001221
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: According to United States Package Insert (USPI)~Route of administration: Intravenous infusion over 30 minutes~Dosage:~* Study part 1: 700, 900 or 1000 mg/m\^2 according to pre-defined dose escalation schedule~* Study part 2: MTD as determined in Study part 1.
Study: NCT00000306
Drug: Dextroamphetamine
Normalized name: Dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03216564
Drug: Calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active vitamin D (Calcitriol) 0.25 micrograms
Study: NCT01098435
Drug: RDC-0313 (ALKS 33)
Normalized name: rh-RdCVF
DrugBank: FOV 2501 (DB17886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules for daily oral administration
Study: NCT03177317
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 8mg IV before chemotherapy on cycle 1 day 1~Once the complete response is achieved, the dose of dexamethasone will be reduced by 2 mg in the next cycle.
Study: NCT03346538
Drug: Continuous infusion low-dose MCI-186
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous injection
Study: NCT00247962
Drug: etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50 mg
Study: NCT00247962
Drug: sulphasalazine (SSZ)
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulphasalazine: The target dose for SSZ is 1.5 g (3 tablets) twice daily orally. Subject start the oral TA at 0.5 g daily for the first week and increase by 0.5 g every week until a daily dose of 3 g. Is achieved by the start of study week 5 of the study.
Study: NCT00770263
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00770263
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02963194
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00841854
Drug: pantoprazole
Normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pantoprazole 40mg bid
Study: NCT00841854
Drug: bismuth
Normalized name: Bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bismuth 300mg qid
Study: NCT00841854
Drug: metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: metronidazole 500mg tid
Study: NCT01849289
Drug: Insulin Degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.
Study: NCT01849289
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.
Study: NCT02142075
Drug: Daptomycin
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00352027
Drug: Vinblastine
Normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV, Day 1 of weeks 1, 3, 5, 7, 9 and 11.
Study: NCT00352027
Drug: Nitrogen Mustard
Normalized name: Nitrogen mustard
DrugBank: Mechlorethamine (DB00888)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV, Day 1 of weeks 1, 5 and 9. Cyclophosphamide may be substituted if nitrogen mustard is unavailable.
Study: NCT00352027
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
Study: NCT00352027
Drug: Bleomycin
Normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
Study: NCT00352027
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV on Days 1 and 2 of weeks 1-10.
Study: NCT00352027
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO every other day of weeks 1-12.
Study: NCT01536886
Drug: Betamethasone plus calcipotriol
Normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00596622
Drug: Lithium
Normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosing will start as one 300-mg capsule per day and will be titrated up to four 300-mg capsules per day for a total of 8 weeks of treatment.
Study: NCT04723342
Drug: Blinatumomab
Normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Blinatumomab, intravenously, as continuous 24 hours infusion 1-7 days - 5 μg/m2/day, 8-28 day - 15 μg/m2/day~1 course after induction treatment
Study: NCT01968629
Drug: Eovist
Normalized name: Eovist
DrugBank: Gadoxetic acid (DB08884)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02872090
Drug: Indacaterol
Normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: inhalation
Study: NCT02872090
Drug: Glycopyrronium
Normalized name: glycopyrronium
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhalation
Study: NCT02872090
Drug: Tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhalation
Study: NCT01371721
Drug: DVS SR
Normalized name: rAAVrh74.MHCK7.DYSF.DV
DrugBank: SRP-6004 (DB16998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a flexible-dose of 20, 25, 35 or 50 mg/day as prescribed by the investigator.
Study: NCT00052494
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00052494
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00052494
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01813149
Drug: phenylephrine and clonidine
Normalized name: Clonidine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be injected with phenylephrine and clonidine at both affected and unaffected sites.
Study: NCT00928642
Drug: imatinib mesylate by mouth
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: imatinib mesylate - 400mg orally, daily on Days 1-5 and 8-12 of a 21 day cycle.
Study: NCT00928642
Drug: Gemcitabine Intravenous
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine - 1000 mg/m2 IV on Day 3 and Day 10 of a 21 day cycle
Study: NCT00086164
Drug: edifoligide (E2F Decoy)
Normalized name: Edifoligide
DrugBank: Edifoligide (DB06556)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04541043
Drug: Nefecon 16mg daily
Normalized name: futibatinib
DrugBank: Futibatinib (DB15149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All study patients received Nefecon 16 mg daily for 9 months.
Study: NCT03698695
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil 5 mg/d and Mefloquine placebo
Study: NCT03770936
Drug: Candesartan
Normalized name: Candesartan
DrugBank: Candesartan (DB13919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 8 mg/day
Study: NCT03770936
Drug: Ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ramipril 1.25 mg/day
Study: NCT03700424
Drug: Trehalose
Normalized name: Trehalose
DrugBank: Trehalose (DB12310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trehalose is a natural disaccharide sugar found extensively among miscellaneous organisms including bacteria, plants, insects, yeast, fungi, and invertebrates. By preventing protein denaturation, it plays various protective roles against stress conditions such as heat, freeze, oxidation, desiccation and dehydration. Owing to this capacity, trehalose is an FDA-approved pharmaceutical excipient that is used as a stabilizer in numerous medicines including parenteral products.~In this study, all injections will be conducted by a trained nurse in the presence of a specialist physician at a duration of 45-90 minutes.
Study: NCT01420523
Drug: Raltegravir-Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raltegravir 400 mg twice a day + Maraviroc 300 mg twice a day
Study: NCT01353976
Drug: Econazole Nitrate Foam 1%
DrugBank: Econazole (DB01127)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Econazole Nitrate Foam 1% applied once a day for 4 weeks
Study: NCT03445780
Drug: Ethyl chloride spray
Normalized name: ethyl chloride Topical Spray
DrugBank: Ethyl chloride (DB13259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin cooling with ethyl chloride spray 5 seconds prior to injection